DYNLL2 (dynein light chain LC8-type 2) functions as a conserved homodimeric hub protein that serves as a non-catalytic accessory component of the cytoplasmic dynein complex, facilitating intracellular retrograde transport along microtubules 1. The protein binds to diverse cellular partners through specific linear motifs, with peptides containing consensus sequences binding with micromolar affinity and exhibiting enthalpy-driven interactions 2. DYNLL2 specifically binds to myosin 5a through an extended motif in the motor's tail region, requiring alternatively spliced exon B for interaction and stabilizing the myosin's coiled-coil domain structure 34. The binding involves structural plasticity, where intrinsically disordered regions fold into β-strands upon DYNLL2 engagement 4. DYNLL2 has been identified as a potential biomarker in various diseases, including osteosarcoma prognosis, ischemic stroke pathogenesis through calcium signaling pathways, and hypertension via PPAR signaling 567. Additionally, DYNLL2 appears in pathways shared between azoospermia and COVID-19, suggesting roles in immune system regulation and infectious disease responses 8. The protein's diverse interactions and disease associations highlight its importance as a regulatory hub in cellular transport and signaling networks.